Medical School

Hematology, Oncology and Transplantation

Department of Medicine

Erica Warlick, MD

UMP - Image - Warlick, Erica

Academic Title

Associate Professor

Clinical Title

Hematologist / Oncologist


  • Cancer
  • Blood Cancer
  • Blood and Marrow Transplantation
  • Leukemia
  • Hematology
  • Hematology/Oncology


  • Masonic Cancer Clinic
  • Blood and Marrow Transplant


Medical School
University of Minnesota, Minneapolis, MN
Johns Hopkins University, Baltimore, MD
Johns Hopkins University, Baltimore, MD

Administrative Contact

E: Georgi Walberg
P: (612) 625-9604
F: (612) 625-6919

Mailing Address

Division of Hematology, Oncology and Transplantation
420 Delaware Street SE, MMC 480
Minneapolis, MN 55455

Bio Statement

Dr. Warlick received her M.D. from the University of Minnesota in 2001 and completed her Internal Medicine residency and fellowships in Medical Oncology and Hematology at Johns Hopkins University in 2007. Dr. Warlick is Medical Director of the Adult Blood and Marrow Transplant Clinic.

Research Interests

Dr. Warlick’s clinical and research efforts focus on the treatment of hematologic malignancies. She has particular interest in myeloid malignancies and the development of new strategies utilizing hematopoietic stem cell transplantation, traditional chemotherapeutics, as well as novel biologic modifiers to treat this diverse group of diseases.

  • Alpha Omega Alpha
  • Champion of Care, Fairview: Patient Recognition 2012
  • Ustun C, Trottier BJ, Sachs Z, DeFor TE, Shune L, Courville E, Holtan SG, Dolan M, Weisdorf DJ, Warlick ED. Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome. Biol Blood Marrow Transplant. 2015 Jan 22 [Epub ahead of print]
  • Warlick ED, Peffault de Latour R, Shanley R, Robin M, Bejanyan N, Xhaard A, Brunstein C, Sicre de Fontbrune F, Ustun C, Weisdorf DF, Socie G. Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type. Biol Blood Marrow Transplant. 2015 Feb;21(2):357-63.
  • Bejanyan N, Oran B, Shanley R, Warlick E, Ustun C, Vercellotti G, Verneris M, Wagner JE, Weisdorf D, Brunstein C. Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation. Bone Marrow Transplant. 2014 Aug;49(8):1029-35.
  • Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients.
    Pease DF, Ross JA, Poynter JN, Nguyen PL, Hirsch B, Cioc A, Roesler MA, Warlick ED.
    Cancer Epidemiol. 2015 Apr;39(2):222-8. doi: 10.1016/j.canep.2015.01.006. Epub 2015 Feb 18.
  • Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.
    Warlick ED, Paulson K, Brazauskas R, Zhong X, Miller AM, Camitta BM, George B, Savani BN, Ustun C, Marks DI, Waller EK, Baron F, Freytes CO, Socie G, Akpek G, Schouten HC, Lazarus HM, Horwitz EM, Koreth J, Cahn JY, Bornhauser M, Seftel M, Cairo MS, Laughlin MJ, Sabloff M, Ringdén O, Gale RP, Kamble RT, Vij R, Gergis U, Mathews V, Saber W, Chen YB, Liesveld JL, Cutler CS, Ghobadi A, Uy GL, Eapen M, Weisdorf DJ, Litzow MR.


  • ©2014 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on January 7, 2016